Effects of Non-selective β-blockers on Mortality of Patients with Cirrhosis and Ascites：A Meta-analysis
- VernacularTitle:非选择性β受体阻滞剂对肝硬化伴腹水患者死亡率影响的Meta分析
- Author:
Xiao CHEN
1
;
Jiaoni ZHENG
1
;
Yao HE
1
;
Yi RUAN
1
;
Yang CHEN
1
;
Xiaoyuan ZHENG
1
Author Information
1. Dept. of Pharmacy，Chongqing Fourth People’s Hospital，Chongqing 400014，China
- Publication Type:Journal Article
- Keywords:
Non-selective β-blockers;
Cirrhosis;
Ascites;
Mortality;
Meta-analysis
- From:
China Pharmacy
2020;31(8):1003-1008
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To syste matically evaluate the effects of non-selective β-blockers（NSBB）on mortality of patients with cirrhosis and ascites ，and to provide evidence-based reference for clinical drug use. METHODS ：Retrieved from PubMed ，the Cochrane Library ，Embase，Web of Science ，CNKI and Wanfang database ，randomized controlled trials （RCTs）and cohort studies about the effects of NSBB on mortality of patients with cirrhosis and ascites were collected from the date of database establishment to Sept. 30th，2019. The patients in the trial group were treated with NSBB ，the patients in the control group were treated with blank control or isosorbidemononitrate ，variceal ligation or other measures to prevent variceal bleeding. After literature screening and data extraction ，the quality of RCTs and cohort studies were evaluated by using bias risk evaluation tool recommended by Cochrane system evaluator manual 5.1.0 and Newcastle-Ottawa scale . Meta-analysis was performed by using Rev Man 5.3 statistical software. RESULTS ：Totally 18 studies were included ，involving 8 649 patients，4 RCTs and 14 cohort studies. Results of Meta-analysis showed that ，there was no significant difference in all-cause mortality between the patients using NSBB of trial group [RR ＝0.85，95％ CI（0.65，1.11），P＝0.22]，severe ascites [RR ＝0.58，95％ CI（0.15，2.22），P＝0.42] or refractory ascites [RR ＝0.85，95％CI（0.61，1.20），P＝0.36] and the control group. Subgroup analysis showed that ，there was no significant difference in all-cause mortality between the patients using NSBB of trial group and control group according to the research method （RCT vs. cohort study ）and the type of drug use （P＞0.05）. CONCLUSIONS ：The use of NSBB does not increase the incidence of all-cause mortality in cirrhosis patients with ascites ，or even in those with severe ascites or refractory ascites.
